Skip to:

Stuart Schweitzer

Professor

Departments

DepartmentsType of Faculty
Health Policy and ManagementFull Time
Contact Information
Phone: 
310.825.2595
Fax: 
310.825.3317

UCLA Fielding School of Public Health / Department of Health Policy and Management / 31-293D CHS

Areas of Interest: 
  • Health Policy
  • Health System Organization and Financing
  • Pharmaceuticals
  • Comparative Health Systems
  • Health Economics and Industrial Policy       

Stuart O. Schweitzer is Professor of Health Policy and Management at the UCLA Fielding School of Public Health. He teaches courses in health economics, health system organization and financing, and pharmaceutical policy.  His publications include over 100 scholarly articles and book chapters, and he has authored four books dealing with Health economics, Intellectual property transfer, pharmaceutical policy, and Industrial policy.   His books include Pharmaceutical Economics and Policy (Oxford University Press) and Health Policy and High-Tech Industrial Development (Edward Elgar), Industrial Policy in the United States:  Breaking the Taboo (Edward Elgar), and Readings in Pharmaceutical Economics and Policy (Edward Elgar) (forthcoming). 

Professor Schweitzer earned his Ph.D. in economics from the University of California, Berkeley. He has taught at Wayne State University and Georgetown University, as well as having been on the research staff of The Urban Institute and the National Institutes of Health. He served as Senior Staff on President Carter's Commission for a National Agenda for the Eighties, where he was responsible for developing national health insurance proposals.  In addition, he has held visiting appointments at Oxford University, CREDES (Paris), ESSEC (Paris), and Fudan University (Shanghai).  He currently holds a Visiting Professor position at the University of Ferrara, in Italy.  

His research interests are in the areas of health policy, especially as they pertain to pharmaceuticals, genetics, industrial policy, and the financing of health care. Dr. Schweitzer recently directed a study of drug pricing in wealthy and developing countries. Another recent project was developing a strategy for the FDA to address the country’s shortage of generic drugs.  He co-directs the UCLA Research Program in Pharmaceutical Economics and Policy.  With a co-author at the University of Ferrara, Professor Schweitzer has recently published a book on industrial policy – the intervention of government into the economic structure of the country.

Education: 
PhD, Economics, University of California Berkeley
Selected Courses: 
HPM 100: Introduction to Health Systems
HPM 205: Pharmaceutical Economics and Policy
HPM 236: Health Economics
HPM 405: Research Seminar in Pharmaceutical Economics and Policy
Selected Publications: 

Books (selected)

Di Tommaso MR and Schweitzer SO, eds., Health Policy and High-Tech Industrial Development: Learning from Innovation in the Health Industry, Cheltenham (UK): Edward Elgar Publishers, 2005.

 

Schweitzer SO, Pharmaceutical Economics and Policy (2nd edition), New York: Oxford University Press, 2007.  Chinese edition published in 2012.

Di Tommaso M.R and Schweitzer SO, Industrial policy in America: Breaking the taboo, (Cheltenham UK:  Edward Elgar Publishers), 2013.

Comanor WS and Schweitzer SO, eds., Readings in Pharmaceutical Economics and Policy, (Cheltenham UK:  Edward Elgar Publishers), 2014 (in press).

 

Articles and Book Chapters (selected)

 

Di Tommaso MR, Paci D, and Schweitzer SO, “Clustering for Intangibles”, in Bianchi P and Labory S, (eds.), The Economic Importance of Intangible Assets, Aldershot: Ashgate, 2004.

 

Di Tommaso MR, Paci D, Rubini L, and Schweitzer SO, “Is Distance Dead?  High-Tech Clusters Analysis and Policy Perspectives”, in Pitelis C, Sugden R, and Wilson JR ,(eds.), Clusters and Globalisation:  The Development of the Economies, Cheltenham:  Edward Elgar, 2004.

 

Di Tommaso M.R., Schweitzer S.O., “Las Pequenas y medianas empresas en industrias de alta tecnologia: la experencia de las empresas biotecnologicas en los Estatos Unidos”,” in Bianchi, P., Parilli M.D., Sugden, R., Alta Tecnologia, productivitad y redes, Città del Messico, Edizioni El Collegio de Tlaxcala, 2005.

 

Di Tommaso, MR, Schweitzer, S.O., "Intangible Clusters of Firms", in Bianchi P and Labory S (eds.), The Economic Importance of Intangible Assets, London: Ashgate, 2005.

 

Schweitzer SO and Di Tommaso MR and, “The Health Industry Model:  New Roles for the Health Industry”, in Di Tommaso and Schweitzer SO, (eds.), Health Policy and High-Tech Industrial Development: Learning from Innovation in the Health Industry, Cheltenham England: Edward Elgar Publishers, 2005.

 

Di Tommaso MR, Paci D, and Schweitzer SO, “The Geography of Intangibles: the case of the Health Industry”, in Di Tommaso MR and Schweitzer SO, (eds.), Health Policy and High-Tech Industrial Development: Learning from Innovation in the Health Industry, Cheltenham England: Edward Elgar Publishers, 2005.

 

Spence M, Teleki S, Cheetham CM, Schweitzer SO, and Millares M, “The effect of direct-to-consumer pharmaceutical advertising on prescribing”, Medical Care Review and Research, 62(5):544-559), 2005.

 

Schweitzer SO, Connell J, and Schoenberg FP, “Clustering in the Biotechnology Industry,” International Journal of Healthcare Technology and Management, 7(6), 2006.

 

Paci D and Schweitzer SO, “Technology policy and social policy:  how industrial policy applies to health”, in Bianchi P and Labory S (eds.) Handbook of Industrial Policy (Cheltenham UK:  Edward Elgar Publishers) 2006.

 

Schweitzer SO and Comanor WS, “Controlling Pharmaceutical Prices and Expenditures:  A Review,” in Andersen RA, Rice TH, and Kominski GF, (eds), Changing the U.S. Health Care System (3rd ed), San Francisco, CA: Jossey-Bass, 2007. (4th edition, with an updated chapter is in press)

 

Schweitzer SO, “Introduction:  How will health systems adopt new genetics technology?”  in Schweitzer SO, ed., Special Issue on Genetics and Society, International Journal of Healthcare Technology and Management 8(5):417-425, 2007.

Comanor WS and Schweitzer SO, “Determinants of drug prices and expenditures,” Managerial and Decision Economics 28:1-14, 2007.

Di Tommaso M.R., Schweitzer S.O, Small and Medium-size Firms in High Technology Industries:  The Experience of Biotechnology Firms in the United States, in D. Parrilli, R. Sugden and P. Bianchi (eds.), High Technology, Productivity and Networks (Basingstoke UK:  Palgrave Macmillan) 2008.

 

Schweitzer SO, “Trying Times at the FDA – The Challenge of Ensuring the Safety of Imported Pharmaceuticals,” New England J of Medicine 358(17):1773-1777, April 24, 2008

Chen Y, Schweitzer SO, “Issues in Drug Pricing, Reimbursement, and Access in China with Reference to the Asia-Pacific Region,” Value in Health 11(Supplement 1:S124-129), 2008.

Barbieri E,  Schweitzer SO, and Galassi FL, “La localizzazione delle imprese biotech in Italia:analysi e implicazioni per le politiche industriali regionali” (“Regionalization of Biotech Industrial Development in Italy:  Analysis and implications for Industrial Districts,” L’Industria 34(4):7-33, 2009.

Di Tommaso, M.R., Schweitzer, S.O., “Percorsi di sviluppo per l’industria italiana. Può “the Health Industry” contribuire al cambiamento?”, in Di Tommaso, M.R., Rubini, L., Paci, D. (eds), L’industria della salute,  (Milano: Franco Angeli) 2009.

Katz G and Schweitzer SO, “Implications of Genetic Testing for Health Policy,” Yale Journal of Health Policy, Law, and Ethics, 10(1):90-134, 2010.

DiTommaso MR and Schweitzer SO (eds), International Journal of Healthcare Technology and Management  11(4) (Special Issue on University-Industry Technology Transfer in the High-Technology Sector), 2010. 

Di Tommaso MR and Schweitzer SO, “The Management of Academic Knowledge and Industrial Development: International Experiences in Health-Industry-Related Sectors,” special issue of International Journal of Healthcare Technology and Management 11(4), 2010.

 

Di Tommaso MR and Schweitzer SO, “Academic Knowledge Production and Transfer: Policy targets and implications for the Health Industry”, International Journal Healthcare Technology and Management, 11(4), 2010.

Schweitzer SO, Comanor WS, and Riddle J, “Drug Prices in Poor Countries are Lower than they are in Wealthy Countries,” Health Affairs 30(8): 1553-1561, 2011.

Schweitzer SO, “How the FDA Can Solve the Prescription Drug Shortage Problem?”  Amer J Public Health, June 2013.

Schweitzer SO and Comanor WS, “Determinants of Pharmaceutical Prices and Expenditures” in Kominski GF, (ed), Changing the U.S. Health Care System (4th ed), San Francisco, CA: Jossey-Bass, 2013. (in press)

Additional Materials (Downloads):